PolyPid Reports Q2 2026 Results: $6.6M Cash, $30M Milestone Achieved, Cash Runway into 2028
PYPD sits 42% above its 52-week low of $3.06 on light trading volume (0.4× avg).
Summary
PolyPid reported Q2 2026 financial results with a net loss of $7.8M and $6.6M in cash as of June 30, but the subsequent $30M Azurity milestone payment extends its cash runway into 2028, strengthening its position ahead of the November 28 PDUFA date.
Key Events · Earnings and Guidance · PYPD
-
Q2 2026 Net Loss Narrows
Net loss of $7.8M ($0.35/share) vs. $10.0M ($0.78/share) in Q2 2025, driven by lower G&A expenses after PSU vesting triggered by positive Phase 3 results.
-
Cash Position and Runway Extended
Cash of $6.6M as of June 30, 2026, but $30M in Azurity milestone payments received post-quarter extends runway into 2028, covering the November 28 PDUFA date and potential early 2027 launch.
-
Azurity Deal Milestone Achieved
Following FDA NDA acceptance, PolyPid achieved the $30M in upfront and near-term milestones from Azurity, with up to $320M in total milestones plus tiered royalties.
-
EU Regulatory Progress
On track for Q3 2026 MAA submission to EMA after productive meetings with rapporteurs; D-PLEX100 under Centralized Procedure for therapeutic innovation.
Analysis · PYPD · Industrial Applications And Services
PolyPid's Q2 2026 financials show a reduced net loss of $7.8M ($0.35/share) versus $10.0M a year ago, with operating expenses declining. The balance sheet held only $6.6M in cash as of June 30, but the company has since received $30M in upfront and near-term milestone payments from Azurity following FDA acceptance of the D-PLEX100 NDA. Management now expects the combined cash position to fund operations into 2028, removing near-term financing risk ahead of the November 28 PDUFA date. The filing also confirms progress toward an EU marketing application in Q3 2026 and pipeline expansion beyond D-PLEX100.
How filings like this one have moved
In the 30 days to Oct 2, 2026, 29.6% of the 1645 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.57%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PYPD was trading at $4.35 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $90.3M. The 52-week trading range was $3.06 to $5.73. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.